[1] 国家药监局批准依沃西单抗注射液上市,Retrieved May 24,2024. From https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240524110617125.html
[2] 拟获优先审评资格,康方生物依沃西上市进程提速,Retrieved Feb 22,2024. From https://mp.weixin.qq.com/s/e0DT-jig6IbAiM-zDOUZmg[3] 康方生物依沃西(PD-1/VEGF双抗,AK112)一线治疗PD-L1表达阳性的NSCLC拟被CDE纳入突破性治疗品种,Retrieved Feb 22,2024. From https://mp.weixin.qq.com/s/3_fMhJi0ZQxRS42RoDSVEA[4] PD-1/VEGF双抗依沃西联合化疗一线治疗NSCLC更新数据发布于欧洲肺癌大会. Retrieved Mar 28,2024. From https://mp.weixin.qq.com/s/T6hKfZV3STAcWA5zSA1C3w[5]依沃西治疗晚期实体瘤临床研究结果重磅发表于《癌症免疫治疗杂志》. Retrieved Apr 23,2024. From https://mp.weixin.qq.com/s/qA-W3OCD9dYIpQ8kcYO_zA
来源:医药观澜